The Placebome: Genetics and the Placebo Response and Its Implications for Trials and Care, a Network Perspective

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d1728773e95">The placebo effect is not mere “noise” in randomized controlled trials (RCTs); it is a biologically mediated phenomenon with measurable inter‑individual variability. The <b>Placebome</b>—the network of gene-related molecules that modulate placebo responsiveness—links polymorphisms in neurotransmitter, reward, stress, and immune pathways to differential clinical improvement following inert treatments. This talk synthesizes emerging evidence that genes impacting dopaminergic, opioidergic, and serotonergic signaling, as well as inflammatory tone, shape placebo trajectories across pain, depression, and other conditions. Recognizing the Placebome challenges long‑held trial assumptions (e.g., strict additivity of drug and placebo effects, sufficiency of blinding, and the confinement of placebo to “subjective” endpoints) and helps explain unexpected null results and site‑to‑site variability.